Inclusion Criteria:~* A voluntary, written informed consent from the patient or the patientÂ´s
representative.~* Male or female patients ≥ 45 years of age as of the date of informed consent.~* Diagnosed
with probable AD according to the National Institute on Aging-Alzheimer's Association \[NIA-AA (2011)\]
criteria.~* MMSE score of ≥ 5 and ≤ 20 during screening period.~* CDR-GS of 2 \~ 3 or GDS of 4 \~ 7 during
screening period.~* Ongoing cholinesterase inhibitor therapy with stable dose of 10 mg/day donepezil
hydrochloride for more than 12 weeks (inclusive) prior to screening, and can continue this therapy until
randomization without any change in the dosage regimen of donepezil hydrochloride.~
